Skip to main content
Premium Trial:

Request an Annual Quote

ZaBeCor Moves siRNA-Based Asthma Drug into Phase II

Premium

Philadelphia-based RNAi drug developer ZaBeCor Pharmaceuticals said this week that it has begun a phase II trial of its siRNA-based treatment for asthma after phase I testing showed the drug to be safe.

The agent, Excellair, is an siRNA targeting the intracellular kinase Syk that is delivered directly to the lung. Although the company had previously said that the drug could reach the clinic in 2007 (see RNAi News, 6/8/2006), it wasn’t until late 2008 that the company announced it had received US Food and Drug Administration clearance to do so (see RNAi News, 11/13/2008).

According to ZaBeCor, the phase I study enrolled asthma patients who received 21 consecutive daily doses of Excellair. No serious adverse effects were observed, and 75 percent of patients with asthma reported an “improved ability to breathe freely or reduced use of their rescue inhaler.” Those receiving placebo reported no improvement.

Specific details about the phase II clinical program were not disclosed. ZaBeCor officials did not return a request for comment.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.